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ABSTRACT
Dalbavancin is a lipoglycopeptide antibiotic
recently approved by the United States Food and
Drug Administration (FDA) for acute bacterial
skin and skin structure infections (ABSSSIs). It is
active against gram-positive pathogens,
including methicillin-resistant Staphylococcus
aureus (MRSA), and minimum inhibitory
concentrations (MICs) are consistently
\0.125 lg/ml, much lower than most other
anti-MRSA agents. Dalbavancin possesses an
extended half-life of over 1 week, allowing an
initial dose of 1000 mg followed by 500 mg
1 week later to complete a course of therapy for
ABSSSI. It is approximately 95% protein bound
and is widely distributed throughout the body,
achieving concentrations similar to plasma levels
in numerous tissues. Against MRSA, dalbavancin
is 4–8 times more potent than vancomycin
in vitro, and limited data suggest it possesses
activity against MRSA with reduced susceptibility
to vancomycin such as hVISA and VISA.
Dalbavancin also possesses in vitro activity
against streptococci and enterococci, although
activity against vancomycin-resistant enterococci
is lacking. In phase 3 ABSSSI studies, dalbavancin
demonstrated similar activity to vancomycin and
provides a more convenient dosing regimen.
Limited phase 2 data suggest dalbavancin also
possesses activity in catheter-related bloodstream
infections. Potential further therapeutic uses
include conditions that require long-term
treatment such as osteomyelitis and infective
endocarditis, although data are currently lacking.
The extended half-life of dalbavancin, along with
its in vitro activity against gram-positive
organisms with reduced susceptibility to other
anti-MRSA antibiotics, suggest it could have an
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INTRODUCTION
Staphylococcus aureus is the leading cause of both
community and hospital-acquired infection in
the United States [1]. Among S. aureus isolates
observed in the United States, between 40% and
50% are methicillin-resistant (MRSA), greatly
reducing therapeutic options. MRSA are
responsible for several serious infections,
including endocarditis, pneumonia,
catheter-associated bloodstream infections,
osteomyelitis, and skin infections.
Vancomycin, a glycopeptide antibiotic derived
in the 1950s from Streptomyces orientalis, has
been the mainstay in anti-MRSA therapy for
more than 50 years [2]. Over this time,
vancomycin has remained remarkably active
against most gram-positive bacterial strains. A
2013 surveillance study of over 2000 MRSA
bloodstream isolates found less than 0.1%
possessed a vancomycin minimum inhibitory
concentration (MIC) of 4 lg/ml, the MIC that
establishes MRSA as a vancomycin-intermediate
susceptible Staphylococcus aureus (VISA)
according to the Clinical and Laboratory
Standards Institute (CLSI) [3]. However,
isolates with reduced susceptibility are
increasing in the literature after first being
reported 20 years ago [4, 5]. Even when
vancomycin therapy is appropriate, the
management of the antibiotic is complicated.
Nephrotoxicity is often associated with
vancomycin therapy, and its narrow
therapeutic index makes it the only currently
available antibiotic with a consensus guideline
statement regarding its dosing [6]. The difficulty
of vancomycin administration, increase of
MRSA with reduced susceptibility to
vancomycin, and toxicities associated with
vancomycin use have led to the recent
development of several novel anti-MRSA
antibiotics.
Dalbavancin is a lipoglycopeptide antibiotic
derived from teicoplanin, an analog of
vancomycin [7]. Dalbavancin is approved for
the treatment of acute bacterial skin and skin
structure infections (ABSSSI) caused by
susceptible, gram-positive isolates [8]. It
possesses a similar spectrum of activity to
vancomycin, including activity against
methicillin-susceptible S. aureus (MSSA) and
MRSA [9]. Owing to its extended half-life,
dalbavancin is dosed once weekly, with only
two doses required for the duration of therapy
[10]. This novel antibiotic possesses several
qualities that make it an interesting addition
to the anti-MRSA armamentarium. This review
will serve to introduce dalbavancin, review
pertinent in vitro and clinical data, and
discuss possible future therapeutic uses for




Dalbavancin is a semisynthetic
lipoglycopeptide derived structurally from
antibiotic A-40926, a teicoplanin-like, natural
antibiotic produced by Nonomuria spp. [11].
Several structural alterations were made in an
attempt to enhance activity against S. aureus as
well as extend the half-life of dalbavancin [11].
Perhaps the most important addition to
dalbavancin is the extended, lipophilic side
chain not present in teicoplanin or A-40926.
This additional side chain allows dalbavancin to
anchor to the bacterial cell membrane,
enhancing its potency, prolonging its half-life,
and allowing for extended dosing intervals [12].
Dalbavancin also possesses an amidated
carboxyl side group that enhances the agent’s
anti-staphylococcal activity. The structure of
dalbavancin is detailed in Fig. 1.
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Like other agents in its class, dalbavancin
exerts its antimicrobial activity through
interaction with terminal D-alanyl-D-alanine
residues of peptidoglycan precursors [13]. The
binding of dalbavancin to these terminal
residues prevents both transpeptidase and
transglycosylase enzymes from catalyzing
peptidoglycan cross-linking and thereby
destroying the integrity of the cell wall,
ultimately causing cell death [12]. Recent data
have demonstrated that the lipophilic side
chain of dalbavancin allows dimerization of
the molecule and anchors dalbavancin to lipid
II in the cellular membrane, strengthening
adherence to the D-alanyl-D-alanine target site
and allowing for enhanced activity compared to
vancomycin and teicoplanin [14].
Microbiology and Resistance
Dalbavancin possesses in vitro activity against
several gram-positive pathogens, including
S. aureus, Streptococcus agalactiae, Streptococcus
pyogenes, Streptococcus anginosus, Enterococcus
faecium, and Enterococcus faecalis, although
activity against enterococci has not been
observed clinically [9, 15–18]. Against
staphylococci and streptococci, dalbavancin
possesses 8–16-fold greater in vitro activity
than vancomycin in broth microdilution MIC
testing [15, 16]. Currently, the FDA has an MIC
breakpoint established for only S. aureus, S.
pyogenes, S. agalactiae, and S. anginosus of
B0.125 lg/ml [8]. Population data of more
than 1100 staphylococci and 300 b-hemolytic
Fig. 1 Chemical structure of dalbavancin
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streptococci isolates from US medical centers in
2012 report dalbavancin MIC50/90 values of
0.06/0.06 and 0.06/0.12 lg/ml, respectively
[15, 16]. Only three staphylococcal isolates
(0.3%) and 14 streptococcal isolates (4%)
possessed dalbavancin MIC values above the
currently proposed FDA breakpoint. Each
resistant streptococcal isolate was a member of
the species S. agalactiae. Against VISA,
vancomycin MIC (4–8 lg/ml) and
heteroresistant VISA (hVISA), dalbavancin
maintains four- to eightfold greater potency
than vancomycin, although the MIC values
largely fall above 0.12 lg/ml [18]. Recently,
Jones and colleagues demonstrated that
vancomycin susceptibility can be considered a
surrogate for dalbavancin susceptibility, as
greater than 99.9% of over 42,000
vancomycin-susceptible isolates were
susceptible to dalbavancin [9]. Against
enterococci, dalbavancin possesses higher MIC
values than it does against other gram-positive
species. Dalbavancin activity against
enterococci is largely contingent upon
vancomycin activity, as 100% of
vancomycin-susceptible Enterococcus faecalis
and E. faecium are inhibited at 0.125 lg/ml
[15, 16]. However, vancomycin-resistant
isolates of each species possess dalbavancin
MIC90 values greater than 4 lg/ml.
Resistance to dalbavancin among
staphylococci is rare, being reported in less
than 1% of isolates [15, 16]. Mechanistically,
there is precedent for reduced vancomycin
susceptibility predicting reduced susceptibility
to dalbavancin. Reduced susceptibility among
hVISA and VISA is mediated through
thickening of the cell wall and increased
D-alanine-D-alanine binding sites [19–21].
These increased binding sites increase the
amount of vancomycin bound to the cell wall,
necessitating higher exposures for similar
efficacy. Although dalbavancin is more potent
at the active site than vancomycin, it is still
inhibited in the same fashion. It remains to be
seen whether the increased potency of
dalbavancin will give it appreciable activity
against these phenotypes clinically.
Vancomycin-resistant S. aureus (VRSA) are
similarly resistant to dalbavancin, although
the mechanism for this resistance is different
than for hVISA and VISA isolates. Vancomycin,
and subsequently dalbavancin, resistance
within VRSA is mediated through a plasmid
gene VanA or VanB carried over from
enterococcal species [22]. These genes are
responsible for altering the D-alanyl-D-alanine
target site to a D-alanyl-D-lactate, rendering
glycopeptide antibiotics ineffective [23].
Interestingly, dalbavancin has in vitro activity
against enterococci with VanB present, but not
against those with VanA [16]. The VanB activity
may be present due to dalbavancin being a
derivative of teicoplanin, which also possesses
activity against enterococci with VanB.
Although this activity is worth noting, the
vast majority of vancomycin-resistant
enterococci in the United States possess VanA
[24]. A complete breakdown of currently
available dalbavancin MIC data against
gram-positive organisms is available in Table 1.
Dosing, Pharmacokinetics,
and Pharmacodynamics
Dalbavancin is currently FDA-approved at a
dose of 1000 mg on day 1 followed by 500 mg
on day 8 for a complete course of therapy for
ABSSSI [8]. Pharmacokinetic data from human
studies demonstrate that dalbavancin possesses
linear, dose-related pharmacokinetics with an
extended elimination half-life of approximately
14.5 days (346 h), allowing for the extended
interval between doses [28–32]. The approved
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Table 1 Dalbavancin MICs for several gram-positive organisms [15–18, 25–27]
Number of isolates MIC50 (lg/ml) MIC90 (lg/ml) Range % Susc.
S. aureus [15–18, 25, 27] 64,843 0.06 0.06 B0.008 to 0.5 99.7
MSSA [15–18, 25, 27] 37,222 0.06 0.06 B0.008 to 0.5 99.7
MRSA [15–18, 25, 27] 27,261 0.06 0.06 B0.008 to 0.5 99.6
hVISA [18] 10 0.25 0.5 0.12 to 0.5 20
VISA [18] 8 0.5 N/A 0.5 to 2 0
DNS SA [25] 37 0.06 0.12 B0.03 to 0.5 91.9
LR SA [25] 19 0.06 0.12 B0.03 to 0.5 100
CNS [15, 16, 27] 473 B0.03 0.06 B0.03 to 0.25 99.6
MS CNS [15, 16, 27] 281 B0.03 0.06 B0.03 to 1 N/A
MR CNS [15, 16, 27] 193 B0.03 0.12 B0.03 to 0.25 N/A
Enterococcus spp. [15, 16] 116 0.06 [4 B0.03 to[4 56
VSE [15, 16] 63 B0.03 0.12 B0.03 to 0.25 96.8
VRE [15, 16] 53 [4 [4 B0.03 to[4 7.5
VanA VRE [15, 16] 49 [4 [4 0.25 to[4 0
VanB VRE [15, 16] 4 B0.03 0.12 B0.03 to 0.12 100
E. faecalis [16] 25 0.06 [4 B0.03 to[4 76
VSE faecalis [16] 19 B0.03 0.06 B0.03 to 0.06 100
VRE faecalis [16] 6 [4 [4 [4 0
E. faecium [16] 31 1 [4 B0.03 to[4 41.9
VSE faecium [16] 11 0.06 0.12 B0.03 to 0.12 100
VRE faecium [16] 20 [4 [4 B0.03 to[4 10
b-hemo strep [15, 16, 26] 1242 B0.03 B0.03 B0.03 to 0.25 98.6
Viridans strep [15, 16, 26] 786 B0.03 B0.03 B0.03 to 0.25 99.7
S. anginosus [26] 190 B0.03 B0.03 B0.03 to 0.06 100
S. milleri [26] 14 B0.03 B0.03 B0.03 to 0.06 100
S. bovis [26] 47 B0.03 0.06 B0.03 to 0.12 100
S. dysgalactiae [26] 50 B0.03 0.06 B0.03 to 0.12 100
S. mitis [26] 305 B0.03 0.06 B0.03 to 0.25 99.7
S. mutans [26] 20 B0.03 0.06 B0.03 to 0.12 100
S. salivarius [26] 49 B0.03 0.06 B0.03 to 0.25 98
GAS [15, 16, 26] 506 B0.03 B0.03 B0.03 to 0.12 100
GBS [15, 16, 26] 287 B0.03 0.12 B0.03 to 0.25 94.4
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dosing regimen was based on a clinical study
evaluating complicated skin and skin structure
infections (cSSSI) in which dalbavancin dosed at
1000 mg initially followed by 500 mg on day 8
was numerically superior to a one-time dose of
1100 mg [33]. Nearly 33% of dalbavancin is
excreted in the urine unchanged, suggesting
that non-renal methods of elimination play an
important role in the metabolism of
dalbavancin [28]. The extended half-life of
dalbavancin is largely due to extensive,
reversible binding to serum albumin,
estimated to be roughly 95% [34]. Among
both healthy subjects and those with varying
degrees of renal dysfunction, the maximum
concentration (Cmax) of dalbavancin falls
between 248 and 312 lg/ml following the
standard 1000 mg initial dose [28, 30].
Dalbavancin exhibits a large volume of
distribution, with an initial average of 8–12 L
and an ultimate volume of distribution of up to
15 L once the drug has distributed throughout
the tissues [32]. Data from nine healthy male
subjects given 1000 mg demonstrate that
dalbavancin maintains concentrations in skin
blister fluid well above current MIC90 values
through 7 days, suggesting that dalbavancin
will be active for the duration of ABSSSI
treatment [35]. In a pharmacokinetic study of
dalbavancin in patients with varying renal and
hepatic function, area under the curve (AUC)
values were markedly elevated over the
treatment duration for patients with creatinine
clearances (CrCl) of 30 ml/min relative to
patients with normal renal function [30].
Because of its reduced clearance, patients with
renal impairment (CrCl\30 ml/min) should
have dalbavancin doses adjusted to 750 mg
initially followed by 375 mg on day 8 for a
complete treatment course. Interestingly,
dalbavancin is not efficiently cleared by
hemodialysis and levels are similar between
patients on dialysis and those with normal
renal function [30]. Therefore, although it
seems contradictory to data in patients with
CrCl \30 ml/min, patients on regularly
scheduled hemodialysis do not require dosage
adjustment. The same study found that hepatic
function had no appreciable affect on
dalbavancin clearance and likely does not
need to be taken into account when dosing,
although caution should be exercised in
moderate to severe hepatic impairment, as
clinical data are limited.
The pharmacokinetic parameter associated
with efficacy of dalbavancin both in vitro and
in vivo is the ratio of AUC to MIC, as is
generally the case with glycopeptides [36]. In
the initial pharmacokinetic studies, bactericidal
concentrations of dalbavancin were present in
Table 1 continued
Number of isolates MIC50 (lg/ml) MIC90 (lg/ml) Range % Susc.
S. pneumoniae [27] 893 B0.03 B0.03 B0.03 to 0.12 100
PSSp [27] 739 B0.03 B0.03 B0.03 to 0.12 100
PISp [27] 120 B0.03 B0.03 B0.03 to 0.12 100
PRSp [27] 34 B0.03 B0.03 B0.03 100
SA S. aureus, MS methicillin-susceptible, MR methicillin-resistant, DNS daptomycin-nonsusceptible, LR linezolid-resistant,
CNS coagulase-negative staphylococci, VSE vancomycin-susceptible enterococci, VRE vancomycin-resistant enterococci,
GAS group A streptococci, GBS group B streptococci, Sp S. pneumo, PS penicillin-susceptible, PI penicillin-intermediate, PR
penicillin-resistant
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serum samples up to 7 days following an initial,
one-time dose of as little as 500 mg [28]. With
regard to the AUC:MIC target, population
pharmacokinetic modeling of dalbavancin
standard dosing from three clinical trials
demonstrated a likelihood of target attainment
of near 100% at dalbavancin MICs up to 0.5 lg/
ml [31]. Similarly, a recent study with 10,000
Monte Carlo simulations of dalbavancin
1000 mg followed by 500 mg 1 week later also
showed a 100% probability of target attainment
for MRSA isolates with dalbavancin MICs up to
0.12 lg/ml [37].
In Vitro and Animal Data
There are in vitro studies that have evaluated
the activity of dalbavancin against
gram-positive organisms, some of which
examined isolates with reduced susceptibility
to vancomycin. In one such study that
evaluated several dalbavancin dose exposures
against S. aureus, continuous concentrations of
3 lg/ml were sufficient to provide bactericidal
activity against both MSSA and MRSA over
20 days [38]. Against VISA, concentrations of
15 lg/ml were bactericidal for 20 days.
Dalbavancin was also studied in combination
with several antibiotics against MSSA, MRSA,
VISA, MRSE, vancomycin-susceptible
enterococci (VSE), S. pyogenes and S.
pneumoniae using broth microdilution
checkerboard techniques [39]. Oxacillin was
synergistic with dalbavancin against MRSA,
VISA, MRSE, and VSE. Among the other agents
tested, including daptomycin, clindamycin,
linezolid, levofloxacin, gentamicin,
quinupristin/dalfopristin, rifampicin, and
vancomycin, none were antagonistic when
combined with dalbavancin against these
bacteria. These in vitro data are limited but
suggest dalbavancin may have activity, either
alone or in combination, against problem
organisms such as VISA.
Dalbavancin has also been studied in several
animal models of infection. When dalbavancin
was evaluated against S. aureus and S.
pneumoniae in neutropenic murine thigh and
lung models, it was determined that AUC:MIC
and Cmax:MIC were both correlated with
dalbavancin activity [36]. These data formed
the dosing regimens used in human studies.
In a study published by Lefort et al.,
dalbavancin possessed activity against
vancomycin-susceptible S. aureus (VSSA) and
VISA dependent upon dose in a rabbit model of
endocarditis [40]. In the authors’ in vitro time kill
studies, dalbavancin possessed superior activity to
teicoplanin and vancomycin against VSSA and
VISA. However, dalbavancin was not bactericidal
in the endocarditis model. The authors postulated
that, due to the enhanced clearance of
dalbavancin in rabbits compared to people, drug
exposures were not appropriate for bactericidal
activity, although they may be in humans.
Further studies evaluating additional dosing
options in the setting of endocarditis are needed.
Dalbavancin has also been studied in a
foreign-body infection model in guinea pigs
both alone and in combination with rifampin
[41]. Dalbavancin alone was unable to eradicate
adherent MRSA, but it was able to prevent
resistance to rifampin. The combination of
agents was effective and superior to either
agent alone, suggesting that rifampin may
play an important role in therapy targeting
biofilm infections.
Clinical Trials
In addition to the study that led to its approval
for ABSSSI, dalbavancin has been previously
evaluated clinically in the setting of
complicated skin and skin structure infections
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(cSSSI) and bloodstream infections. In a phase
II, multicenter, non-inferiority, randomized
controlled trial, 2 weeks of twice daily
vancomycin was compared to standard-dose
dalbavancin against catheter-related
bloodstream infections (CR-BSI) due to
gram-positive pathogens [42]. Patients were
C18 years old with signs of bacteremia and at
least one of the following: intravascular catheter
present at the start of infection, absence of any
other likely source of infection, and either
microbiologically documented gram-positive
bacteremia or C2 signs of bacteremia. Patients
were excluded if they had impaired renal or
hepatic function, recently received
immunosuppressive therapy, prolonged
neutropenia, received prior antibiotic active
against gram-positive bacteria within 48 h of
enrollment, S. aureus bacteremia within the
previous 3 months, or an alternative source of
infection. The primary outcome was overall
efficacy at the follow-up visit defined by
clinically and microbiologically documented
responses among patients with a bacterial
pathogen identified at study entry. Clinical
success was defined as resolution of signs and
symptoms of CR-BSI such that no additional
treatment was warranted. Seventy-five patients
were randomized to treatment, of which 67
were included in efficacy analyses. Baseline
characteristics were similar, although slightly
more females were enrolled in the vancomycin
group. Coagulase-negative staphylococci and S.
aureus were the primary pathogens isolated,
with a higher proportion of S. aureus (32.1%)
reported as MRSA in the vancomycin group
compared to the dalbavancin group (19.2%).
The overall success rate was 87% for
dalbavancin compared to 50% for vancomycin
(p\0.05), and both treatment groups were
more successful with catheter removal. This
effect carried across the microbiological
intention to treat cohort at both end of
therapy and test of cure visits, and the effect
was also present among the evaluable
population at both time points. Adverse effects
reported by study patients were generally mild,
and no patients discontinued dalbavancin due
to adverse effects. In the vancomycin group,
three patients withdrew therapy due to adverse
effects, with one patient perhaps experiencing
renal toxicity due to vancomycin. The data
from this study demonstrated the efficacy of
dalbavancin 1000 mg on day 1 followed by
500 mg 1 week later against uncomplicated,
gram-positive bacteremia. Although not
directly demonstrated by the study, the
authors postulated that the increased peak
levels and lipophilic tail of dalbavancin might
have aided it in clearance of biofilm on infected
catheters, perhaps explaining the enhanced
efficacy.
Gram-positive pathogens also frequently
cause skin infections, and they are a large
source of healthcare expenditures with over 15
million infections annually in the United States
[43]. Owing to the convenient dosing of
dalbavancin and its ability to keep patients
out of infusion centers, two published studies
have evaluated dalbavancin for the treatment of
ABSSSI against active comparators [10, 33]. In a
phase II, randomized controlled study, Seltzer
et al. evaluated dalbavancin given as either a
single 1100 mg dose or 1000 mg followed by
500 mg 1 week later against several
standard-of-care regimens for skin and
soft-tissue infection (SSTI) [33]. Sixty-two
patients were enrolled in the study, and
patients were C18 years old with SSTI
suspected or known to be caused by a
gram-positive pathogen. Infections were
required to involve deep tissue or require
surgical intervention, and patients were
required to have C2 symptoms of SSTI. Of
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note, patients with creatinine clearance\50 ml/
min were excluded. The primary efficacy
endpoint was clinical cure or improvement at
follow-up visit. Failure was defined as
persistence of C1 systemic sign or symptom of
SSTI that required further therapy. The study
also reported dalbavancin pharmacokinetics. At
follow-up visit, a higher proportion of 2-dose
dalbavancin patients achieved cure in the
intention-to-treat population (19/21, 91%)
compared to 1-dose dalbavancin (12/20, 60%)
or comparator regimen (16/21, 76%).
Dalbavancin concentrations remained [30 lg/
ml for 1 week after the 1100 mg dalbavancin
dose, and concentrations remained [20 lg/ml
for 20 days in patients who received 1000 mg
followed by 500 mg. Adverse effects were mild
and considered to be unrelated to study drug.
The data from this study established that
dalbavancin is likely optimally dosed at
1000 mg with a supplementary 500 mg dose
1 week later for skin infections.
Jauregui et al. were the first to evaluate
dalbavancin at 1000 mg followed by 500 mg
1 week later in a phase III trial for the treatment
of cSSSI [44]. The study was a multicenter,
non-inferiority trial comparing dalbavancin to
linezolid for 14 days. Enrollment criteria were
similar to the study by Seltzer and colleagues.
The primary end point was clinical success,
defined as the lack of necessary further
antibacterial therapy. The treatment groups
were similar at baseline except for a higher
proportion of vascular disease in the
dalbavancin group. The average age was
47 years, and 62% of patients were male.
Abscess (32%) and cellulitis (28%) were the
primary types of infection. Efficacy at
test-of-cure for dalbavancin was 88.9% and
was 91.2% for linezolid (lower limit CI
-7.28%), which achieved non-inferiority. The
vast majority of cultured isolates were from
abscesses, with 90% of those isolates being S.
aureus, and dalbavancin and linezolid cured
91% and 89% of these isolates, respectively.
Adverse events were generally mild, and adverse
events related to treatment were higher in the
linezolid arm compared to dalbavancin
(32.2–25.4%, respectively).
Boucher and colleagues evaluated
dalbavancin dosed at 1000 mg followed by
500 mg in two phase III, randomized controlled
trials comparing dalbavancin to standard
therapy against ABSSSI, DISCOVER 1 and
DISCOVER 2 [10]. Standard therapy consisted
of at least 3 days of intravenous vancomycin
followed by an optional switch to oral linezolid
for the completion of 10–14 days of therapy. The
two trials were identically designed,
double-dummy, international, non-inferiority
studies, allowing for pooling of data. Patients
were included who were C18 years old and were
diagnosed with ABSSSI. The diagnosis of ABSSSI
was based on cellulitis, a major abscess, or wound
infection with an area of at least 75 cm2, which is
about the area of a modern smart phone. Patients
were eligible if they were likely to require at least
3 days of intravenous antibiotics and possessed
at least one systemic sign of infection. In the
DISCOVER trials, enrollment was limited to a
maximum of 30% of patients with abscess,
owing to high cure rates in these patients with
incision and drainage alone, and at least 25% of
patients had fever, establishing a less healthy
population than previous studies. Per recent FDA
guidance, the primary endpoint was cessation of
spread of erythema and a temperature of
B37.6 C at 48–72 h. More than 85% of patients
enrolled possessed temperaturesC38 C, and the
median size of infection was 343 cm2. The
majority of patients were white (89.3%) with a
mean age of 49.5 years. Greater than 50% of
patients met SIRS criteria, and\26% of patients
had abscesses.
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In the pooled dalbavancin group, 525 of 659
patients (79.7%) had a successful outcome
compared to 521 of 653 patients (79.8%) in
the standard therapy group (95% CI -4.5 to
4.2), meeting the criteria for non-inferiority.
Missing temperature data was the primary
reason for failure in both treatment arms and
was the primary treatment-related reason for
failure. The two arms were similarly successful
in patients with bacteremia, as 23 of 23
patients (100%) in the dalbavancin arm had
negative cultures at follow-up and 12 of 14
patients (85.7%) in the standard therapy arm
had negative cultures. Clinical success was
similar between the arms according to
infection type, severity of illness, and severity
of infection. Each treatment regimen was[97%
successful against documented MRSA skin
infection.
More patients in the standard therapy arm
experienced an adverse event (645 vs. 540,
p = 0.05) compared to patients in the
dalbavancin arm, and the total number of
treatment-related adverse events was higher in
the standard therapy arm as well (183 vs. 139,
p = 0.02). However, serious adverse events were
similar between the groups. The most common
adverse events were nausea, diarrhea, and
pruritus, and each occurred in \3% of
patients. Only two patients in the study, both
in the vancomycin-linezolid arm, experienced
nephrotoxic adverse effects.
The data from this study suggest that
dalbavancin is similarly efficacious to standard
therapy against ABSSSI with regard to the newly
established FDA criteria. The patients in this
study were quite sick, with [85% possessing
fever and more than half meeting SIRS criteria,
demonstrating that dalbavancin can be an
effective alternative to therapy with
vancomycin and linezolid, especially in the
case of suspected MRSA infection. The
incidence of serious adverse effects is low and
has been similar to all comparator arms.
Currently, dalbavancin is being evaluated in
a phase 3b study to compare the FDA-approved
dose against a one-time dose of 1500 mg for
ABSSSI (ClinicalTrials.gov NCT02127970). The
results have yet to be published, but preliminary
data presented in a press release suggest that the
one-time dose of 1500 mg is similar to the
two-dose regimen with regard to C20%
reduction in ABSSSI lesion size at 48–72 h.
Although conclusions cannot be made without
the full breadth of data available, it does appear
that dalbavancin may be efficacious and safe
with a one-time dose, further enhancing its
therapeutic ease of use.
Safety and Drug Interactions
The safety of dalbavancin has been evaluated in
several clinical and pre-clinical studies.
Combined phase II and phase III data thus far
have revealed the most common adverse effects
to be nausea (5.5%), headache (4.7%), diarrhea
(4.4%), vomiting (2.8%), rash (2.7%), and
pruritus (2.1%) [10, 28–30, 33, 42]. In the
phase II study of CR-BSI, dalbavancin patients
experienced more hypokalemia (6/33, 18%) and
hypotension (7/33, 21%) than those treated
with vancomycin, although these trends did
not continue across other studies [42].
Additionally, dalbavancin has demonstrated a
0.8% rate of ALT levels greater than three times
the upper limit of normal, although these have
been reversible with treatment cessation [8]. In
the phase III clinical trials, treatment-related
adverse events were fewer in the dalbavancin
arms compared to treatment with vancomycin
or linezolid [10, 44]. In contrast to the
nephrotoxic effects often associated with
glycopeptides, dalbavancin has not been
associated with nephrotoxicity to date.
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Although increased nephrotoxicity was not
demonstrated in the vancomycin arms of
comparator trials, nephrotoxicity is a
historically demonstrated adverse effect of
vancomycin, and the lack of reduced renal
function with dalbavancin therapy is
encouraging. Although further safety data are
needed, it appears that dalbavancin has a
favorable renal safety profile. Due to potential
concern for QTc prolongation with telavancin,
another lipoglycopeptide antibiotic,
dalbavancin has recently been studied at
therapeutic and supratherapeutic doses, and
dalbavancin caused no increase in QTc
interval [45, 46]. Because dalbavancin has such
an extended half-life, there has been some
concern regarding the potential for long-term
adverse effects. To date, no adverse effects have
been demonstrated up to 28 days after
treatment cessation [10]. However, long-term
data are still limited, and post-approval adverse
effect reporting will shed more light on any
long-term effects.
Several studies have evaluated dalbavancin
pharmacokinetics in the presence of known
cytochrome P450 inducers, substrates, and
inhibitors to determine the presence of
significant drug interactions [28, 32].
Unsurprisingly, dalbavancin was not affected
by co-administration of other agents, as
dalbavancin is not cleared by the P450
metabolic pathway. The available evidence
suggests that dalbavancin can be administered
without regard to agents known to affect the
P450 pathway.
CONCLUSION
With options for the treatment of resistant
staphylococcal infections limited and
vancomycin susceptibility demonstrating signs
of decline, dalbavancin presents an exciting
therapeutic alternative. It has evidenced an
excellent safety and efficacy profile in the
setting of ABSSSI and has gained FDA approval
for this indication. ABSSSI infections continue
to be a large healthcare burden, and the
availability of a two-dose therapeutic regimen
has important implications for patient
adherence, potential hospital avoidance, and
cost savings versus inpatient therapy.
Emergency departments and observational care
units stand to benefit especially, as patients will
be able to be easily transitioned back into the
community after being seen for only a limited
amount of time. Perhaps most exciting are the
clinical opportunities for dalbavancin use
outside of its current approved indication.
Dalbavancin has already demonstrated efficacy
in CR-BSI, and further studies will be important
to determine its place in deep-seated infections
such as pneumonia, osteomyelitis, and
endocarditis. Preliminary data are promising,
as dalbavancin achieves concentrations in bone
tissue well above staphylococcal MIC90 values
14 days after a 1000 mg dose [47]. Going
forward, it will be imperative to determine
optimal dosing strategies for infections that
require weeks-long durations of therapy. Owing
to the activity dalbavancin possesses in vitro
and in vivo against S. aureus with reduced
vancomycin susceptibility, further study
involving dalbavancin against these isolates is
also intriguing and warranted. It remains to be
seen whether antibiotic combinations with
dalbavancin will display similar additive
effects as they do with vancomycin and
daptomycin against gram-positive pathogens.
Dalbavancin has the potential to be an effective
agent to combat resistant gram-positive
organisms, and expanded use of this agent
post-approval will help determine its ultimate
place in therapy.
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